Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aditxt Inc ADTX

Healthcare Biotechnology
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc... see more

Recent & Breaking News (NDAQ:ADTX)

Aditxt Announces Closing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants

Business Wire December 6, 2021

Aditxt Extends the Timeline to Sign the Definitive Agreement to Acquire AiPharma Global to December 16, 2021

Business Wire December 2, 2021

Aditxt Announces Pricing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Led by Leading Healthcare Investor

Business Wire December 1, 2021

Aditxt Announces Proposed Public Offering of Common Stock and Warrants

Business Wire November 30, 2021

The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff's Office, to Become First in the Nation to Deploy AditxtScore(TM) for Immune Scoring for its Employees and First Responders

Business Wire November 22, 2021

Aditxt Webinar at 2pm ET to Explore PRESECO Results

Business Wire November 12, 2021

Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC

Business Wire November 12, 2021

Aditxt Partners With CLX Health to Offer AditxtScore(TM) for COVID-19 Immune Monitoring Service Through CLX's TrustAssure(TM) Platform

Business Wire November 3, 2021

Aditxt Announces Closing of $4.25 Million Public Offering

Business Wire October 20, 2021

Aditxt to Present at the Dawson James 6th Annual Small Cap Growth Conference in Florida on October 21, 2021

Business Wire October 20, 2021

Aditxt Announces Pricing of $4.25 Million Public Offering

Business Wire October 18, 2021

Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021

Business Wire October 7, 2021

AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak.

PR Newswire October 5, 2021

Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada

Business Wire October 5, 2021

Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization

Business Wire September 27, 2021

Aditxt, Inc. and SphereDX Launch AditxtScore(TM) for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots

Business Wire September 9, 2021

Aditxt Announces Closing of $11 Million Registered Direct Offering, and Funding of Bridge Loan Satisfying a Key Term of its Letter of Intent for Planned Acquisition of Commercial Stage Pharma Company with Anti-Viral COVID-19 Therapy

Business Wire September 7, 2021

Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Business Wire August 26, 2021

Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19

Business Wire August 25, 2021

Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic

Business Wire August 11, 2021